Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer, previously treated metastatic hormone receptor–positive, HER2-negative breast cancer, and metastatic urothelial cancer.
Read the full article on WikipediaUnresectable locally advanced or metastatic triple-negative breast cancer Clinical criteria: Treatment Phase: Initial treatment Patient must have progressive disease following two or more prior systemic therapies, at least one of them in the locally advanced or metastatic setting, AND The condition must be inoperable, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation, AND The treatment must be the sole PBS-subsidised therapy for this PBS indication.
“Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. Linkage to an antibody allows the drug to specifically target cells expressing Trop-2.”
Working under the parallel aged-care framework? Aged-care equivalent →